Revenue: As of FY2025 Q3, the actual value is USD 2.934 M.EPS: As of FY2025 Q3, the actual value is USD -0.08.EBIT: As of FY2025 Q3, the actual value is USD -715 K.<h3>Segment Revenue</h3><ul><li>Contract Manufacturing: Revenue was $907 thousand for the three months ended September 30, 2025, compared to $864 thousand for the same period in 2024. For the nine months ended September 30, 2025, revenue was $2,718 thousand, compared to $1,890 thousand for the same period in 2024.</li><li>Custom and White Label Finished Goods: No revenue was recorded for the three months ended September 30, 2025 and 2024. Revenue was $27 thousand for the nine months ended September 30, 2025, compared to $42 thousand for the same period in 2024.</li><li>Branded Consumer Products: Revenue was $1,918 thousand for the three months ended September 30, 2025, compared to $1,930 thousand for the same period in 2024. For the nine months ended September 30, 2025, revenue was $5,584 thousand, compared to $3,515 thousand for the same period in 2024.</li><li>Medical Devices/Other: Revenue was $109 thousand for the three months ended September 30, 2025, compared to $146 thousand for the same period in 2024. For the nine months ended September 30, 2025, revenue was $296 thousand, compared to $200 thousand for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Gross profit was $1,243 thousand for the three months ended September 30, 2025, compared to $1,155 thousand for the same period in 2024. For the nine months ended September 30, 2025, gross profit was $3,690 thousand, compared to $1,674 thousand for the same period in 2024.</li><li>Operating Expenses: Operating expenses were $1,968 thousand for the three months ended September 30, 2025, compared to $1,943 thousand for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $5,828 thousand, compared to $4,387 thousand for the same period in 2024.</li><li>Net Loss: Net loss was - $647 thousand for the three months ended September 30, 2025, compared to - $754 thousand for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $1,965 thousand, compared to - $2,639 thousand for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was - $1,592 thousand for the nine months ended September 30, 2025, compared to - $3,008 thousand for the same period in 2024.</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities was - $28 thousand for the nine months ended September 30, 2025, compared to - $712 thousand for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $1,671 thousand for the nine months ended September 30, 2025, compared to $2,079 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to maintain and grow its existing contract manufacturing business, continue building and developing its catalogue of consumer products, and develop proprietary medical devices and drug delivery programs. The company also intends to explore new product channel sales in consumer products and expand its customer base to provide financial stability and long-term shareholder value creation.</li><li>Non-Core Business: The company continues to evaluate strategic initiatives, including acquisitions, and additional capital raises through debt or equity may be necessary to achieve these objectives.</li><li>Priority: The company expects to continue incurring losses in the near term and aims to manage and grow its current products to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings.</li></ul>

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.934 M